WHY IT MATTERS: Children with drug-resistant epilepsy whose families cannot afford private prescriptions may continue to go without a treatment option that has demonstrated clinical evidence, simply because NHS commissioning has not kept pace with the legal changes already on the books. CLINICAL OVERVIEW: Drug-resistant epilepsy in children, particularly conditions like Dravet syndrome and Lennox-Gastaut syndrome, represents one of the most compelling and well-documented areas for cannabinoid-based medicine, with cannabidiol demonstrating meaningful seizure reduction in controlled clinical trials. Despite the rescheduling of cannabis-based medicines in the UK following high-profile advocacy, NHS access remains severely limited by prescribing restrictions, funding barriers, and a shortage of specialists willing to initiate treatment.